WBO:SDZ (Switzerland)
Â
Registered Shares
€
77.98
-1.34 (-1.69%)
Jun 26
Business Description
Sandoz Group AG
ISIN : CH1243598427
Share Class Description:
WBO:SDZ: Registered SharesTotal Employee Number:
23,000Compare
Compare
Traded in other countries / regions
SDZ.Switzerland0SAN.UKSDZNY.USAD8Y.GermanySDZN.MexicoSDZ.Austria IPO Date
2025-10-23Description
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.43 | |||||
Debt-to-Equity | 0.61 | |||||
Debt-to-EBITDA | 2.86 | |||||
Interest Coverage | 6.47 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.64 | |||||
Beneish M-Score | -2.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.4 | |||||
3-Year EBITDA Growth Rate | -0.4 | |||||
3-Year EPS without NRI Growth Rate | 15.9 | |||||
3-Year FCF Growth Rate | -4.9 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 13.54 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 7.22 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 69.64 | |||||
9-Day RSI | 70.1 | |||||
14-Day RSI | 66.97 | |||||
3-1 Month Momentum % | 6.61 | |||||
6-1 Month Momentum % | 12.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.18 | |||||
Quick Ratio | 0.77 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 187.03 | |||||
Days Sales Outstanding | 79.24 | |||||
Days Payable | 109.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.11 | |||||
Forward Dividend Yield % | 1.11 | |||||
5-Year Yield-on-Cost % | 1.11 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | -0.27 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.35 | |||||
Operating Margin % | 12.76 | |||||
Net Margin % | 8.18 | |||||
EBITDA Margin % | 17.67 | |||||
FCF Margin % | 7.23 | |||||
OCF Margin % | 14.26 | |||||
ROE % | 10.05 | |||||
ROA % | 4.17 | |||||
ROIC % | 6 | |||||
3-Year ROIIC % | 1.33 | |||||
ROC (Joel Greenblatt) % | 53.33 | |||||
ROCE % | 9.43 | |||||
Years of Profitability over Past 10-Year | 3 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 42.81 | |||||
Forward PE Ratio | 22.4 | |||||
PE Ratio without NRI | 24.58 | |||||
PS Ratio | 3.5 | |||||
PB Ratio | 4.16 | |||||
Price-to-Free-Cash-Flow | 48.44 | |||||
Price-to-Operating-Cash-Flow | 24.57 | |||||
EV-to-EBIT | 29.9 | |||||
EV-to-Forward-EBIT | 17.43 | |||||
EV-to-EBITDA | 21.63 | |||||
EV-to-Forward-EBITDA | 13.79 | |||||
EV-to-Revenue | 3.82 | |||||
EV-to-Forward-Revenue | 3.16 | |||||
EV-to-FCF | 52.89 | |||||
Earnings Yield (Greenblatt) % | 3.34 | |||||
FCF Yield % | 2.09 |
GF Valueâ„¢
Sandoz Group AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sandoz Group AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 09:00 | In 124 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 123 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 37 days | ||
| CHF 0.800000 Cash Dividend | 2026-04-13 | 72.22 (+1.63%) | ||
| General meeting for 2026 | 2026-04-09 | 70.96 (+1.60%) | ||
| Jefferies Pan-European Mid-Cap Conference | 2026-03-25 | 65.36 (+0.55%) | ||
| BNP Paribas Exane Healthcare Conference | 2026-03-24 | 65.60 (+3.18%) | ||
| Bank of America Pharma Bus Tour | 2026-03-12 | 68.10 (-1.59%) | ||
| Barclays Global Healthcare Conference | 2026-03-10 | 69.88 (+1.75%) | ||
| Guidance call for 2025 | 2026-03-03 | 74.12 (-1.93%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Sandoz Group AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers